Cinacalcet,
does it really help with Serum calcium normalization in inoperable primary hyperparathyroidism?
research showsThe grade is C with 50 points. In a 67-participant double-blind placebo-controlled trial, corrected serum calcium normalized to 10.3 mg/dL or lower in 75.8% with cinacalcet versus 0% with placebo (P<0.001). This is a laboratory surrogate and does not establish fewer fractures or kidney stones.
ads claimMarketing must not convert calcium normalization into prevention of long-term complications. The trial established normalization but did not test reductions in fractures or kidney stones.
Useful facts when choosing a product
- Cinacalcet sensitizes the calcium-sensing receptor and lowers parathyroid hormone and serum calcium.
- Cinacalcet is a reimbursed prescription medicine in South Korea and requires specialist prescribing and calcium monitoring.
- Nausea occurred in 30% versus 18% and muscle spasms in 18% versus 0%; no hypocalcemic event occurred in either group. Vomiting was not separately reported as a leading adverse event in this paper.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.cinacalcet.UNK.serum-calcium-normalization-in-inoperable-primary-hyperparathyroidism.assess.placeboUnknown > Cinacalcet > Unknown > Serum calcium normalization in inoperable primary hyperparathyroidism > Association or change assessment > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
This multinational phase 3 trial randomized 67 participants 1:1 to cinacalcet or placebo for up to 28 weeks. Double blinding and placebo control were feasible and were used. Limitation name: total sample of 67. Avoidability: possible - although this was a rare, surgery-ineligible population that was difficult to recruit, longer multinational enrollment could have expanded the trial beyond 200 participants. The sponsor stopped enrollment after regulatory approval; this resource-related early stop was treated as a precision issue rather than counted again as bias. Amgen supported the trial, and author affiliations included Amgen (Europe) GmbH and Amgen Inc.
Why this is classified as C (50)
The primary endpoint was surrogate serum calcium normalization, imposing a C ceiling, and the evidence is one 67-participant Amgen-sponsored trial, giving C with 50 points.
Counterpoint. The grade does not deny the clinical value of controlling calcium when surgery is impossible; it identifies the lack of long-term clinical-event evidence.
Rejudgment record. Cross-check applied — Cross-checked the paper and registration for 67 participants, double-blind placebo control, calcium normalization, Amgen support and employee affiliations, and adverse events
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Serum calcium normalization | C | Normalization was clear at 75.8% versus 0%, but it is a surrogate endpoint. |
| Reduction in fractures or kidney stones | ? | The trial did not test these clinical events. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Khan A et al. 2015 | Multinational phase 3 randomized double-blind placebo-controlled trial | 67 randomized participants | Sponsored by Amgen with Amgen employee coauthors | Normalization of mean corrected serum calcium to 10.3 mg/dL or lower | 75.8% versus 0%; absolute difference 75.8 percentage points; P<0.001 | Pivotal single manufacturer-funded surrogate-endpoint trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Final verification and publication gate: Codex · Evidence date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Cinacalcet Benefits Serum Calcium Normalization in Primary Hyperparathyroidism When Surgery Is Not Possible — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/joint-bone/cinacalcet-inoperable-primary-hyperparathyroidism-calcium-normalization/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.